白细胞介素-1β在获得性耐肿瘤坏死因子相关凋亡诱导配体的肺癌H460迁移中的作用  

Contribution of IL-1β to migration of lung cancer H460 cells with acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand

作　　者：朱郇悯[1] 汤娟娟[1] 季小芳 温镇成 高志岩[2] 李孜[1] 

机构地区：[1]广州医科大学基础学院霍夫曼免疫研究所,510182 [2]广州医科大学形态学实验中心,510182

出　　处：《实用医学杂志》2016年第7期1080-1083,共4页The Journal of Practical Medicine

基　　金：广东省自然科学基金项目(编号:2015A030313469)

摘　　要：目的:探讨高水平IL-1β和获得性耐肿瘤坏死因子相关凋亡诱导配体(TRAIL)的肺癌H460细胞迁移的相互作用。方法:通过RT-PCR,Western Blot和酶联免疫吸附试验检测H460-TR和野生型H4608(H460-WT)中IL-1β的水平;通过细胞迁移实验检测细胞迁移能力;通过对H460细胞施加或不施加IL-1或者IL-1R的拮抗剂检测人重组磷脂酰肌醇-3-激酶/丝苏氨酸蛋白激酶(PI3K/Akt)的迁徙范围和活性。结果:在条件培养基中的H460-TR细胞的迁徙能力和其IL-1β水平高于H460-WT细胞。肺癌H460细胞的迁徙徙能力和Akt活性和IL-1β水平一致。结论:癌症细胞中IL-1β的显著升高与H460-TR的高迁徙能力以及Akt活性是相互关联的。Akt信号是IL-1β的下游通路,IL-1β可能可以作为转移性肺癌的药物作用靶点。Objective To determine the association of high IL-1β levels with the migration of lung cancer H460 cells with acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand（TRAIL）.Methods The resistant cells were referred to as H460-TR in this study. IL-1β levels in H460-TR cells and the parent H460（H460-WT） cells were measured through RT-PCR, Western blot, and enzyme-linked immunosorbent assay. The migration capacity of the cells was determined using the migration transwell assay. The extent of migration and the activation of phosphatidyl-inositol 3-kinase / serine-threonine kinase（PI3K / Akt） were detected in H460 cells treated with or without human recombinant IL-1 or IL-1R antagonist. Results Migration capacity of H460-TR cells in the conditioned medium and its IL-1β level were higher than those of H460-WT cells.The migration capacity and Akt activation were consistent with the IL-1β level in lung cancer H460 cells.Conclusions Significantly elevated IL-1β expression in cancer cells is associated with the high migration capacity of H460-TR cells, and Akt activation. Akt signaling as the downstream pathway of IL-1β and IL-1βmay function as a therapeutic target for metastatic lung cancer.

关 键 词：肺肿瘤 IL-1Β 肿瘤坏死因子相关凋亡诱导配体 AKT 迁徙能力 

分 类 号：R734.2[医药卫生—肿瘤]